MedTrace Logo

COVIDOM: Longterm Morbidity of SARS-CoV-2 Infection and COVID-19 Disease - Consequences for Health Status and Quality of Life

NCT04679584 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2020-12-22

No results posted yet for this study

Summary

COVID-19 is a novel disease caused by SARS-CoV-2 that primarily affects the lungs but also various other organs of the body already in early stages of the disease. Due to the multiple organ involvements in the acute phase, it is conceivable that - in a significant proportion of patients - longterm sequels in various organ systems might occur, thereby impacting the individual's health status and quality of life; and posing a relevant burden to the resources of the health care system

Assessment of SARS-CoV-2-longterm morbidity and sequels on the population level:

In order to identify and treat these sequels in a timely fashion and to get a sense of the prevalence of such SARS-CoV-2 sequels on the population level, it is important to collect follow-up data and to comprehensively re-examine a population-representative sample of SARS-CoV-2 infected individuals.

Within the COVIDOM study we will conduct deep clinical and biochemical phenotyping in population-representative samples in Germany. This will allow novel insights into disease pathogenesis and chronicity of virus infections.

Conditions

Interventions

OTHER

Observation of different courses of SARS-CoV-2 infection in different phases (acute vs. post-acute) and settings

Oberservatory Cohorts focusing (I) on subjects after SARS-CoV-2 infection that are recruited from the general population (POP), and on subjects with acute SARS-CoV-2 infections recruited (II) in university hospital high-care settings or (III) general health care

Sponsors & Collaborators

  • Charite University, Berlin, Germany

    collaborator OTHER

  • Wuerzburg University Hospital

    collaborator OTHER

  • German Federal Ministry of Education and Research

    collaborator OTHER_GOV

  • University Hospital Schleswig-Holstein

    lead OTHER

Principal Investigators

  • Stefan Schreiber, Prof. Dr. · Internal Medicine Department I, UKSH Kiel

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-16
Primary Completion
2021-12-31
Completion
2030-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04679584 on ClinicalTrials.gov